149 related articles for article (PubMed ID: 36923305)
1. Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI; Wang Y; Pierce RH; Campbell JS; Yushak M; Milhem M; Ross M; Niland K; Arbeit RD; Parasuraman S; Bickley K; Yeung CC; Aicher LD; Smythe KS; Gan L
Cancer Res Commun; 2022 Aug; 2(8):904-913. PubMed ID: 36923305
[TBL] [Abstract][Full Text] [Related]
2. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
[TBL] [Abstract][Full Text] [Related]
5. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
[TBL] [Abstract][Full Text] [Related]
6. Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Gandhi S; Pandey MR; Attwood K; Ji W; Witkiewicz AK; Knudsen ES; Allen C; Tario JD; Wallace PK; Cedeno CD; Levis M; Stack S; Funchain P; Drabick JJ; Bucsek MJ; Puzanov I; Mohammadpour H; Repasky EA; Ernstoff MS
Clin Cancer Res; 2021 Jan; 27(1):87-95. PubMed ID: 33127652
[TBL] [Abstract][Full Text] [Related]
7. IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.
Gordy JT; Sandhu AK; Fessler K; Luo K; Kapoor AR; Ayeh SK; Hui Y; Schill C; Chen F; Wang T; Karanika S; Sunshine JC; Karakousis PC; Markham RB
Front Immunol; 2022; 13():1074644. PubMed ID: 36741387
[TBL] [Abstract][Full Text] [Related]
8. Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.
Blood; 2023 Jun; 141(26):3232. PubMed ID: 37383001
[No Abstract] [Full Text] [Related]
9. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
10. Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.
Clancy-Thompson E; Perekslis TJ; Croteau W; Alexander MP; Chabanet TB; Turk MJ; Huang YH; Mullins DW
Cancer Immunol Res; 2015 Aug; 3(8):956-67. PubMed ID: 26048575
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
12. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.
Saxena R; Wang Y; Mier JW
Melanoma Res; 2020 Feb; 30(1):14-25. PubMed ID: 31524789
[TBL] [Abstract][Full Text] [Related]
14. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4
Zmajkovicova K; Pawar S; Maier-Munsa S; Maierhofer B; Wiest I; Skerlj R; Taveras AG; Badarau A
Genes Immun; 2022 Sep; 23(6):196-204. PubMed ID: 36089616
[TBL] [Abstract][Full Text] [Related]
16. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.
Badolato R; Alsina L; Azar A; Bertrand Y; Bolyard AA; Dale DC; Deyà-Martinez À; Dickerson KE; Ezra N; Hasle H; Kang HJ; Kiani-Alikhan S; Kuijpers TW; Kulagin A; Langguth D; Levin C; Neth O; Olbrich P; Peake J; Rodina Y; Rutten CE; Shcherbina A; Tarrant TK; Vossen MG; Wysocki CA; Belschner A; Bridger GJ; Chen K; Dubuc S; Hu Y; Jiang H; Li S; MacLeod R; Stewart M; Taveras AG; Yan T; Donadieu J
Blood; 2024 Apr; ():. PubMed ID: 38643510
[TBL] [Abstract][Full Text] [Related]
18. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
19. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
Mao Y; Gide TN; Adegoke NA; Quek C; Maher N; Potter A; Patrick E; Saw RPM; Thompson JF; Spillane AJ; Shannon KF; Carlino MS; Lo SN; Menzies AM; da Silva IP; Long GV; Scolyer RA; Wilmott JS
J Transl Med; 2023 Apr; 21(1):257. PubMed ID: 37055772
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
